Persomed develops an innovative, personalized vaccine against colorectal cancer
With support from:
An affordable vaccine that is widely deployable
A subsidy of 2 million euro
The ICON project is executed by the Persomed consortium, which consist of myNEO, QbD, Antleron and VUB.
Realizing a breakthrough
The development of an effective personalized colorectal cancer vaccine which can be widely deployed.
"The ICON project reflects a thirst for innovation and offers a significant potential for curing cancer."
- Hilde Crevits, Flemish minister van Innovation.
Further developing and refining personalized cell therapy
Persomed further builds on the vaccine which has already been developed to the needs of individual patients with advanced colorectal cancer. Through the ICON project, the cell therapy is further developed and refined towards an effective, safe, affordable vaccine which can be produced on a larger scale following a standardized approach.
2024: official registration for widespread use
Proof of concept and phase I clinical study involving minimum eight patients
Executing the therapy on a larger group of selected patients
Broad vaccine usage and extrapolation to other forms of cancer
One project, four pairs of shoulders
Cancer cells develop from normal cells through accumulations of mutations in the genome. These mutations are cancer specific and differ from patient to patient. Some of these mutations, giving rise to epitopes, hold the key as they can be recognized as foreign by the immune system.
The four partners of Persomed with various expertise’s will identify and isolate these patient-specific immune-activating epitopes in favor of a targeted treatment:
"The Persomed partners are absolutely convinced that more personalized therapies potentially enable to put a stop to this disease."
- Bart Van Acker, CEO QbD
The immune-activating dendritic cells of every individual patient, stimulate the immune system like a vaccine.
This personalised therapy potentially enables to put a stop to colorectal cancer and make it widely deployable
More effective than chemo
Today's one-size-fits-all therapies are no longer sufficient for large groups of patients. Personalized therapies are inherently more effective in putting a stop to the disease.